John Welsh

John Welsh

Auto-generated profile, based on publicly available information

John Welsh

Downstream Biologics Process Research and Development, Merck & Co., Inc. Rahway, NJ 07065, USA

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 July 2020 in Biotechnology and Bioengineering
Verified
Journal Article
Closed access
PDF file
DRDavid Roush
David Roush
DADilip Asthagiri
Dilip Asthagiri
DBDeenesh K. Babi
Deenesh K. Babi
SBSteve Benner
Steve Benner
CBCamille Bilodeau
Camille Bilodeau
OZOleksandr Zavalov
Oleksandr Zavalov

10 June 2024 in Biotechnology and Bioengineering
Verified
Journal Article
Closed access
PDF file
FWFelix Wittkopp
Felix Wittkopp
JWJohn Welsh
John Welsh
RTRobert Todd
Robert Todd
ASArne Staby
Arne Staby
DRDavid Roush
David Roush
DBDeenesh Babi
Deenesh Babi

6 May 2023 in Biotechnology and Bioengineering
Verified
Journal Article
Closed access
ZLZhao Li
Zhao Li
JCJustin Chen
Justin Chen
KMKirby Martinez‐Fonts
Kirby Martinez‐Fonts
MRMichael Rauscher
Michael Rauscher
SRShannon Rivera
Shannon Rivera
SKSunitha Kandula
Sunitha Kandula

23 January 2025 in Biotechnology Progress
Verified
Journal Article
Closed access
JWJohn P. Welsh
John P. Welsh
SAScott H. Altern
Scott H. Altern
JLJessica Y. Lyall
Jessica Y. Lyall
SBSean Burgess
Sean Burgess
MRMichael A. Rauscher
Michael A. Rauscher
CWChris Williams
Chris Williams

25 February 2025 in Journal of Chromatography A
Verified
Journal Article
Closed access
MHMichael Hartmann
Michael Hartmann
MRMichael Rauscher
Michael Rauscher
JRJulie Robinson
Julie Robinson
JWJohn Welsh
John Welsh
DRDavid Roush
David Roush

28 June 2012
Verified
Book Chapter
Open access
TRTimothy P.L. Roberts
Timothy P.L. Roberts
MGMichael Gandal
Michael Gandal
SSSteven Siegel
Steven Siegel
PVPaulo Vianney-Rodrigues
Paulo Vianney-Rodrigues
JWJohn P. Welsh
John P. Welsh
This chapter describes the syndromes of mild cognitive impairment (MCI) and Alzheimer's disease (AD). Many elderly persons exhibit MCI, characterized by memory complaints and mild abnormalities of performance on formal tests, associated with intact general cognition and preserved activities of daily living. The clinical manifestations of AD arise from abnormalities involving brain regions and neural circuits composed of populations of neurons that are essential for memory, learning, and cognitive performance. Early information about the involvement of neurotransmitter-specific circuits damaged by the disease led to the design of early therapies for AD. The genetics of AD are complex, often influencing phenotype in an age-dependent manner. Late onset cases of AD without clear familial association reflect the influences of a variety of risk factors. The chapter emphasizes the need for safe and effective mechanism-based therapies for AD. New treatments will probably require combinatorial approaches.